非小细胞肺癌患者EGFR-TKI靶向治疗前后肿瘤体积变化规律及其临床价值

doi:10.13481/j.1671-587x.20160229

Abstract

Abstract:

Objective: To explore the regular variation pattern of tumor volumes of the patients with non-small cell lung cancer(NSCLC)before and after targeting treatment of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), and to clarify its clinical value.Methods: The materials of 39 NSCLC patients with EGFR-TKI targeting treatment were retrospectively analyzed. The tumor volumes were detected by volume measurement software of TPS and Image J image processing software, then the absolute and relative tumor volume changes of the NSCLC patients before and after targeting treatment were analyzed by paired sample comparison symbol Wilcoxon rank test. Results: The absolute tumor volumes(mm³) of the patients with NSCLC before and 1 month after targeting treatment were 14822.11(7524.73, 54999.41)and 7954.42(3499.73, 29396.83), respectively, and there was statistically significant difference(Z=-3.257, P=0.001);the absolute tumor volumes of the patients with NSCLC 1 and 2 months after targeting treatment were 8 358.47(4394.36, 24 430.05)and 7028.76(3634.98, 21056.71), respectively, and there also was statisticaliy significant difference(Z=-2.213, P=0.027).When the original tumor volume before targeting treatment was regarded as 1, the relative tumor volume of 1 month after targeting theatment was 0.612 6(0.313 8, 0.853 7), and there was significant difference(Z=-3.855, P<0.001);the relative tumor volumes of 1 month and 2 months after targeting treatment were 0.6084(0.3643, 1.0443) and 0.423 0(0.248 8, 0.877 7), respectively, and there also was statistically significant differernce(Z=-2.173, P=0.030);but the differences between other consecutive months(from 3 months to 6 months) had no statistically significant differences(P>0.05);the changes of tumor relative volume presented platform stage after 3 months.The tumor relative volumes of 7-9 months after EGFR-TKI treatment reached the bottom. Conclusion: The average primary tumor volume of the NSCLC patients is obviously reduced 1 and 2 months after TKI targeting treatment.It may be optimal to carry out radiotherapy in 3-9 months after EGFR-TKI targeting treatment.

Key words: carcinoma,non-small-cell lung, tumor volume, epidermal growth factor receptor tyrosine kinase inhibitors, radiotherapy

CLC Number:

R734.2

ZOU Xi, CHEN Jinmei, HONG Jinsheng, GUO Feibao, LAN Linzhen, ZHANG Weijian. Tumor volume recession pattern of patients with non-small cell lung cancer before and after EGFR-TKI targeting treatment and its clinical value[J].Journal of Jilin University Medicine Edition, 2016, 42(02): 345-350.

References

[1] 李夏南,朱广迎. EGFR-TKI联合放疗治疗晚期非小细胞肺癌的研究进展[J].中国肺癌杂志,2014,17(4):357-362.

[2] Chang CC,Chi KH,Kao SJ,et al.Upfront gefitinib/erlotinib treatmentfollowed by concomitant radiotherapy for advanced lung cancer:Amono-institutional experience[J].Lung Cancer,2011,73(2):189-194.

[3] WangJ,Xia TY,Wang YJ,et al.Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2011,81(3):e59-65.

[4] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(1):67-78.

[5] Chen G,Feng J,Zhou C,et al.Quality of life (QoL) analyses from OPTIMAL (CTONG-0802),a phase Ⅲ,randomised,open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)[J].Ann Oncol,2013,24(6):1615-1622.

[6] 中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟.晚期非小细胞肺癌分子靶向治疗专家共识(2013版)[J].中华结核与呼吸杂志,2014,37(3):177-183.

[7] 庄梦琪.晚期非小细胞肺癌靶向药物治疗失败模式的临床分析[D].济南:山东大学,2014.

[8] 张纬建,邹喜,洪金省,等.非小细胞肺癌诱导化疗后肿瘤体积变化规律及其影响因素[J].广东医学,2013,34(11):1741-1744.

[9] 邹喜.非小细胞肺癌化疗后肿瘤体积变化规律及其影响因素研究[D].福州:福建医科大学,2012.

[10] Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.

[11] Zhang L,Ma S,Song X,et al.Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer(INFORM:C-TONG0804):a multicentre,double-blind randomised phase 3 trial[J].Lancet Oncol,2012,13(5):466-475.

[12] Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatmenl for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL,CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncol,2011,12(8):735-742.

[13] Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncol,2010,11(2):121-128.

[14] Alexander BM,Othus M,Caglar HB,et al.Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2011,79(5):1381-1387.

[15] Akamatsu H,Inoue A,Mitsudomi T,et al.Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer:combined analysis of two Phase Ⅲ trials (NEJ 002 and WJTOG 3405)[J].Jpn J Clin Oncol,2013,43(6):664-668.

Tumor volume recession pattern of patients with non-small cell lung cancer before and after EGFR-TKI targeting treatment and its clinical value

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZHONG Lili, ZHAO Yinlong, LI Bingjin, ZOU Xiaohan, CHENG Ziqian, CUI Ranji. Effects of MicroRNA-210 on growth and radiosensitivity of ovarian cancer cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 265-269.
[2]	WANG Qin, DU Liqing, WANG Yan, XU Chang, LI Jin, LIU Qiang. Inhibitory effect of Rb94 gene combined with radiotherapy on growth of esophageal carcinoma cells of tumor-bearing nude mice [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 220-224.
[3]	SUN Xiaomei, XIA Wenming, JIANG Xin, CHEN Xiang, LI Tao, QU Yaqin. Comparison of dosimetry between RapidArc and 5F-IMRT in treatment of locally advanced pancreatic carcinoma [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 365-368.
[4]	XU Zhaonan, BI Ye, WANG Xi, ZHANG Zebing, WANG Shuyu, JIANG Siwen, JIA Jie. Influence of antophagy in radiation sensitivities of oral squamous cell carcinoma CAL-27 and KB cells and its mechanisms [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 716-720.
[5]	ZHOU Jieping, WANG Peng, QIAN Liting, WU Aidong. Dosimetric comparison between IMRT and a single full arc,two full arc VMAT for postoperative cervical cancer patients [J]. Journal of Jilin University Medicine Edition, 2016, 42(01): 120-124.
[6]	WANG Peng, ZHOU Jieping, ZHAN Bihong, QIAN Liting, WU Aidong, FU Jie. Comparison of dose distribution between 5F-IMRT,VMAT, and Gyro-knife radiotherapy plans for small lung masses [J]. Journal of Jilin University Medicine Edition, 2015, 41(05): 1044-1049.
[7]	ZHANG Mao,SU Qing-xiu,YANG Jin-lei,JIN Hai-guo,DONG Ying,WU Dan，WANG Fu-xiang. Comparison of dosimetric parameters of re-irradiation in patients with locally recurrent nasopharyngeal carcinoma [J]. Journal of Jilin University Medicine Edition, 2014, 40(05): 1085-1089.
[8]	LIANG Shuo,WANG Zhi-cheng,LI Yan-bo,GUO Cai-xia,GONG Shou-liang,LIN Cheng-he. Inhibitory effect of pshuttle-Egr-1-hSmac plasmid combined with X-ray irradiation on proliferation of breast cancer MDA-MB-435 cells [J]. Journal of Jilin University Medicine Edition, 2014, 40(05): 913-919.
[9]	HUANG Xiong，CAI Chuan-shu. Relationship between acute radiation pneumonitis after intensity modulated radiation therapy in patients with non-small cell lung cancer and parameters of dose-volume histogram [J]. Journal of Jilin University Medicine Edition, 2014, 40(04): 892-894.
[10]	LI Jing-jing，LIU Ming-bo，HOU Yu-fei，XU Shan， KONG De-juan，LIANG Bing， HE Meng-zi，LIANG Nan，MA Shu-mei，LIU Xiao-dong. Killing effects of autophagy on lung cancer cells indifferent kinds of radiotherapy methods combined with chemotherapy and related mechanisms  [J]. Journal of Jilin University Medicine Edition, 2013, 39(6): 1098-1102.
[11]	ZHOU Hui,YANG Bing,TANG Quan,SUN Yuan-ming,HAN Yin,FAN Fei-yue,LIU Xiao-dong,JIA Li-li. Effect of ionizing radiation on expression of RANK in differentiation process of osteoclasts and its molecular mechanism of bone injury  [J]. Journal of Jilin University Medicine Edition, 2013, 39(6): 1127-1131.
[12]	WANG Fu-xiang,PIAO Jin-xia,SU Qing-xiu,ZHANG Mao. Evaluation on efficacy of different doses of weekly cisplatin chemotherapy in treatment  of stage ⅡB－ⅣA cervical cancer [J]. Journal of Jilin University Medicine Edition, 2013, 39(2): 352-356.
[13]	LI Yan-bo,WANG Zhi-cheng\|ZHANG Yan-qiu\|DONG Li-hua,LIU Yang,LI Jin-hua. Effects of TRAIL and endostatin double-gene-radiotherapy on proliferation,cell cycle procession and apoptosis \|in human vascular endothelial \|cells [J]. J4, 2012, 38(4): 611-617.
[14]	LIU Chun-Li, WANG Yue, CHE Yan-Hai　. Effect of \|extrinsic vascular endothelial growth factor on viability of \|skin flap treated with radiotherapyin rat at different time \|after operation [J]. J4, 2009, 35(5): 893-897.
[15]	YU Lei,WANG Tie-jun,WANG Jian-feng,LIU Li-bo,JU Gui-zhi. Detection of chromosome aberration rate and micronucleus rate in patients with esophageal carcinoma before and after radiotherapy 　and clinical significances [J]. J4, 2007, 33(4): 737-740.